Abstract

Typhoid fever is endemic in most countries, causing major public health problems with high morbidity and mortality, the resistance of Salmonella enterica serovar Typhi (S. Typhi) towards antimicrobials is recently increased. The aim was to detect the harboring gyrA gene in Typhi Salmonella enterica serovar. Twenty Salmonella enterica serovar Typhi isolates were obtained from the Teaching laboratories of the medical city in Baghdad, the isolates were obtained from blood specimens from typhoid patients. Colonies of Salmonella enterica serovar Typhi appeared on CHROM agar and Xylose Lysine Deoxycholate Agar (XLD) as light mauve to mauve-colored and as red with black center colonies, respectively. Polymerase Chain Reaction (PCR) technique was used to detect the presence of the gyrA gene within the twenty isolates with specific primer. All twenty isolates show the highest resistance rates to Cefazolin 18 (90%), Ciprofloxacin 16 (80%), and Nalidixic acid 15 (75%), while it shows highest sensitivity rates to Cefepime 18 (90%) and Tobramycin 16 (80%) antibiotics. The MIC values show equal to or more than breakpoint of Nalidixic acid and Ciprofloxacin were 15 (75%) and 16 (80%) isolates, respectively. PCR results showed the presence of gyrA gene (488 bp) in 14 (70%) of isolates (isolate number 1, 2, 3, 4, 7, 8, 9, 10, 12, 13, 14, 15, 18 and 19). On the other hand, 6(30%) isolates (isolate numbers 5, 6, 9, 11, 16, 17, and 20) don't harbor the gyrA gene.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.